In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocycline. A randomized prospective comparative study should be performed to confirm our encouraging results
Cascio, A., Scarlata, F., Giordano, S., Antinori, S., Colomba, C., & TITONE LANZA DI SCALEA, L. (2003). Treatment of human brucellosis with rifampin plus minocycline. JOURNAL OF CHEMOTHERAPY, 15(3), 248-252.
Data di pubblicazione: | 2003 |
Titolo: | Treatment of human brucellosis with rifampin plus minocycline |
Autori: | |
Citazione: | Cascio, A., Scarlata, F., Giordano, S., Antinori, S., Colomba, C., & TITONE LANZA DI SCALEA, L. (2003). Treatment of human brucellosis with rifampin plus minocycline. JOURNAL OF CHEMOTHERAPY, 15(3), 248-252. |
Rivista: | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
Treatment of human brucellosis with rifampin plus minocycline.pdf | N/A | Open Access Visualizza/Apri |